SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tuck8/1/2016 11:38:02 AM
1 Recommendation

Recommended By
Lance Bredvold

  Read Replies (3) of 3661
 
There are various firesales today, but to me the most interesting is Inotek (ITEK) off some 24% (edit: now 27%) on announcement of convertible notes that haven't even been priced yet. The company has a P3 trial for glaucoma going, but they only have one drug. Their P2 data looked solid enough:

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 and 4 Weeks of Twice-Daily Ocular Trabodenoson in Adults with Ocular Hypertension or Primary Open-Angle Glaucoma.

The treatment period in the P3, however, runs 3x longer. Results are due within the next 6 months.

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma (MATrX-1)

Don't know if anyone else here follows it. Obviously, some risk. I nibbled am eensy bit this morning at $7.35, a bit early, it seems.

I han't follow the company closely, but intend to going forward, as I am on watch for glaucoma due to pitting in a couple of spots in my optic nerves.

Would be interested to hear others takes on the company, but it should probably be moved to the tif or valuation threads.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News